Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report

Ipilimumab and nivolumab combination therapy is effective against unresectable or metastatic renal cell carcinoma. However, it is associated with many immune-related adverse events, including hypophysitis that is difficult to diagnose early because of non-specific initial symptoms. Herein, we report...

Descripción completa

Detalles Bibliográficos
Autores principales: Motonaga, Aoi, Nakanishi, Shotaro, Tanaka, Kei, Nishida, Sho, Izumi, Keiichiro, Saito, Seiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040277/
https://www.ncbi.nlm.nih.gov/pubmed/33868946
http://dx.doi.org/10.1016/j.eucr.2021.101661
_version_ 1783677754811613184
author Motonaga, Aoi
Nakanishi, Shotaro
Tanaka, Kei
Nishida, Sho
Izumi, Keiichiro
Saito, Seiichi
author_facet Motonaga, Aoi
Nakanishi, Shotaro
Tanaka, Kei
Nishida, Sho
Izumi, Keiichiro
Saito, Seiichi
author_sort Motonaga, Aoi
collection PubMed
description Ipilimumab and nivolumab combination therapy is effective against unresectable or metastatic renal cell carcinoma. However, it is associated with many immune-related adverse events, including hypophysitis that is difficult to diagnose early because of non-specific initial symptoms. Herein, we report the case of a 54-year-old man with metastatic renal cell carcinoma who developed hypophysitis after receiving ipilimumab and nivolumab combination therapy. The initial symptom was headache. However, endocrine tests showed decreased levels of cortisol, free thyroxine and thyroid-stimulating hormone. Moreover, magnetic resonance imaging revealed pituitary enlargement. Accordingly, we diagnosed hypophysitis and immediately started hydrocortisone replacement therapy, which improved the symptoms.
format Online
Article
Text
id pubmed-8040277
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80402772021-04-15 Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report Motonaga, Aoi Nakanishi, Shotaro Tanaka, Kei Nishida, Sho Izumi, Keiichiro Saito, Seiichi Urol Case Rep Oncology Ipilimumab and nivolumab combination therapy is effective against unresectable or metastatic renal cell carcinoma. However, it is associated with many immune-related adverse events, including hypophysitis that is difficult to diagnose early because of non-specific initial symptoms. Herein, we report the case of a 54-year-old man with metastatic renal cell carcinoma who developed hypophysitis after receiving ipilimumab and nivolumab combination therapy. The initial symptom was headache. However, endocrine tests showed decreased levels of cortisol, free thyroxine and thyroid-stimulating hormone. Moreover, magnetic resonance imaging revealed pituitary enlargement. Accordingly, we diagnosed hypophysitis and immediately started hydrocortisone replacement therapy, which improved the symptoms. Elsevier 2021-03-26 /pmc/articles/PMC8040277/ /pubmed/33868946 http://dx.doi.org/10.1016/j.eucr.2021.101661 Text en © 2021 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Oncology
Motonaga, Aoi
Nakanishi, Shotaro
Tanaka, Kei
Nishida, Sho
Izumi, Keiichiro
Saito, Seiichi
Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
title Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
title_full Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
title_fullStr Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
title_full_unstemmed Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
title_short Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
title_sort hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040277/
https://www.ncbi.nlm.nih.gov/pubmed/33868946
http://dx.doi.org/10.1016/j.eucr.2021.101661
work_keys_str_mv AT motonagaaoi hypophysitisinducedbyipilimumabandnivolumabcombinationtherapyforadvancedrenalcellcarcinomaacasereport
AT nakanishishotaro hypophysitisinducedbyipilimumabandnivolumabcombinationtherapyforadvancedrenalcellcarcinomaacasereport
AT tanakakei hypophysitisinducedbyipilimumabandnivolumabcombinationtherapyforadvancedrenalcellcarcinomaacasereport
AT nishidasho hypophysitisinducedbyipilimumabandnivolumabcombinationtherapyforadvancedrenalcellcarcinomaacasereport
AT izumikeiichiro hypophysitisinducedbyipilimumabandnivolumabcombinationtherapyforadvancedrenalcellcarcinomaacasereport
AT saitoseiichi hypophysitisinducedbyipilimumabandnivolumabcombinationtherapyforadvancedrenalcellcarcinomaacasereport

Ejemplares similares